Compare · COR vs HKPD
COR vs HKPD
Side-by-side comparison of Cencora Inc. (COR) and Cellyan Biotechnology Co. Ltd (HKPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and HKPD operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $60.29B, about 3994.4x HKPD ($15.1M).
- Over the past year, COR is up 8.2% and HKPD is down 72.7% - COR leads by 80.9 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- COR has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cencora Inc.
- Cellyan Biotechnology Co. Ltd
- Price
- $309.71+1.54%
- $0.35-2.64%
- Market cap
- $60.29B
- $15.1M
- 1M return
- +8.87%
- -5.79%
- 1Y return
- +8.22%
- -72.66%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 2
- 2
- Recent ratings
- 25
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest COR
- Executive Vice President Battaglia Silvana was granted 58 shares, increasing direct ownership by 0.25% to 23,624 units (SEC Form 4)
- Executive Vice President Campbell Elizabeth S was granted 50 shares, increasing direct ownership by 0.16% to 30,756 units (SEC Form 4)
- Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
- SEC Form 4 filed by Chief Financial Officer Boratto Eva C
- New insider Boratto Eva C claimed ownership of 3 shares (SEC Form 3)
- Director Tyler Lauren M bought $148,626 worth of shares (550 units at $270.23), increasing direct ownership by 14% to 4,359 units (SEC Form 4)
- Director Durcan Dermot Mark bought $1,096,760 worth of shares (4,000 units at $274.19), increasing direct ownership by 14% to 31,767 units (SEC Form 4)
- SEC Form 11-K filed by Cencora Inc.
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Announces Samantha Hammock as Chief Human Resources Officer
Latest HKPD
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-3 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 3 filed by new insider Chan Kam Leung
- New insider Wong Lap Sun claimed ownership of 18,468 units of Class A Ordinary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Wang Zifeng
- SEC Form 3 filed by new insider Liu Shu
- SEC Form 3 filed by new insider Zhou Mike Yao
- SEC Form 3 filed by new insider Wu Jingyan